Ladenburg Thalmann upgraded Codexis (NASDAQ:CDXS) to “buy” from “neutral” with a new price target of $6.25. The shares were quoted at $4.65 in afternoon trading on Jan. 4.Read More
H.C. Wainwright has launched coverage of Codexis (NASDAQ:CDXS) with a “buy” rating and $6 price target. The stock closed at $4.23 on Tuesday.
Codexis is a biotechnology services company that specializes in the development of novel, high-efficiency biocatalysts used in manufacturing processes.Read More